chloroquine - for COVID-19 method

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA
clinical improvement 1.40 [0.83, 2.37]> 10%1 study (- / 1)89.6 %criticalnot evaluable very lowcrucial-
clinical improvement (time to event analysis only) 1.40 [0.83, 2.37]> 10%1 study (- / 1)89.6 %criticalnot evaluable very lowcrucial-
PCR-negative conversion 1.08 [0.64, 1.83]> 10%1 study (- / 1)61.3 %criticalnot evaluable very lowimportant-
PCR-negative conversion (14-day) 6.08 [2.74, 13.48]> 10%1 study (- / 1)100.0 %criticalnot evaluable very lowimportant-
PCR-negative conversion (time to event analysis only) 1.08 [0.64, 1.83]> 10%1 study (- / 1)61.3 %criticalnot evaluable very lowimportant-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



This meta-analysis covered 1 pathologies: 87,95,94,90,91,97 95